Hypoxia-Inducible Factors: Master Regulators of Cancer Progression

Trends in Cancer

Volumn 2, Issue 12, 2016, Pages 758-770

  Schito, Luana ^a   Semenza, Gregg L ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

oxygen biology; tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1;

ANGIOGENESIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CIRCULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; EXTRAVASATION; HUMAN; HYPOXIA; IMMUNE EVASION; METABOLISM; METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; ANIMAL; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 85004065577     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.10.016     Document Type: Review

References (90)

1. 1 Prabhakar, N.R., Semenza, G.L., Oxygen sensing and homeostasis. Physiology (Bethesda) 30 (2015), 340–348.
2. 2 Duan, C., Hypoxia-inducible factor 3 biology: complexities and emerging themes. Am. J. Physiol. Cell Physiol. 310 (2016), C260–C269.
3. 3 Semenza, G.L., Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29 (2010), 625–634.
4. 4 Deeb, G., et al. Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk. Res. 35 (2011), 579–584.
5. 5 Frolova, O., et al. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol. Ther. 13 (2012), 858–870.
6. 6 Morine, Y., et al. Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 58 (2011), 1439–1444.
7. 7 Zheng, S-S., et al. Prognostic significance of HIF-1α expression in hepatocellular carcinoma: a meta-analysis. PLoS One, 8, 2013, e65753.
8. 8 Rey, S., Semenza, G.L., Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc. Res. 86 (2010), 236–242.
9. 9 Du, R., et al. HIF-1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 (2008), 206–220.
10. 10 Lee, K., et al. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 2353–2358.
11. 11 Lee, K., et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 17910–17915.
12. 12 Carmeliet, P., Jain, R.K., Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10 (2011), 417–427.
13. 13 Rapisarda, A., Melillo, G., Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat. Rev. Clin. Oncol. 9 (2012), 378–390.
14. 14 Semenza, G.L., HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123 (2013), 3664–3671.
15. 15 Luo, W., et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145 (2011), 732–744.
16. 16 Pescador, N., et al. Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1. PLoSOne, 5, 2010, e9644.
17. 17 Favaro, E., et al. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab. 16 (2012), 751–764.
18. 18 Chiche, J., et al. Tumor hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J. Cell. Mol. Med. 14 (2010), 771–794.
19. 19 Sonveaux, P., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118 (2008), 3930–3942.
20. 2 sensing, mitochondria and ROS signaling: the fog is lifting. Mol. Aspects Med. 47–48 (2016), 76–89.
21. 21 Tello, D., et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1α decreases oxygen consumption by inhibiting Complex I activity. Cell Metab. 14 (2011), 768–779.
22. 22 Chan, S.Y., et al. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 10 (2009), 273–284.
23. 23 Favaro, E., et al. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and Krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One, 5, 2010, e10345.
24. 24 Huang, D., et al. HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation Is critical for cancer progression. Cell Rep. 8 (2014), 1930–1942.
25. 25 Metallo, C.M., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481 (2012), 380–384.
26. 26 Wise, D.R., et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 19611–19616.
27. 27 Gameiro, P.A., et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 17 (2013), 372–385.
28. 28 Sun, R.C., Denko, N.C., Hypoxic regulation of glutamine metabolism through HIF-1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 19 (2014), 285–292.
29. 29 Intlekofer, A.M., et al. Hypoxia induces production of L-2-hydroxyglutarate. Cell Metab. 22 (2015), 304–311.
30. 30 Koivunen, P., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483 (2012), 484–488.
31. 31 Bensaad, K., et al. Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 9 (2014), 349–365.
32. 32 Ye, J., et al. Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. 4 (2014), 1406–1417.
33. 33 Samanta, D., et al. PHGDH is required for mitochondrial redox homeostasis, breast cancer stem cell maintenance and lung metastasis. Cancer Res. 76 (2016), 4430–4442.
34. 34 Zhang, H., et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31 (2012), 1757–1770.
35. 35 Schito, L., et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2707–E2716.
36. 36 Wong, C.C-L., et al. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J. Mol. Med. (Berl.) 90 (2012), 803–815.
37. 37 Lamouille, S., et al. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15 (2014), 178–196.
38. 38 Gilkes, D.M., Semenza, G.L., Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 9 (2013), 1623–1636.
39. 39 Gilkes, D.M., et al. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E384–E393.
40. 40 Rankin, E.B., et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 13373–13378.
41. 41 Chou, C-C., et al. A novel HIF-1α-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1α expression and epithelial-mesenchymal transition in cancer cells. Oncotarget 6 (2015), 8271–8285.
42. 42 Rankin, E.B., Giaccia, A.J., Hypoxic control of metastasis. Science 352 (2016), 175–180.
43. 43 Gilkes, D.M., et al. Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J. Biol. Chem. 288 (2013), 10819–10829.
44. 44 Gilkes, D.M., et al. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol. Cancer Res. 11 (2013), 456–466.
45. 45 Gilkes, D.M., et al. Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res. 73 (2013), 3285–3296.
46. 46 Wong, C.C-L., et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 16369–16374.
47. 47 Jin, F., et al. New insight into the SDF-1/CXCR4 axis in a breast carcinoma model: hypoxia-induced endothelial SDF-1 and tumor cell CXCR4 are required for tumor cell intravasation. Mol. Cancer Res. 10 (2012), 1021–1031.
48. 48 LaGory, E.L., Giaccia, A.J., The ever-expanding role of HIF in tumour and stromal biology. Nat. Cell Biol. 18 (2016), 356–365.
49. 49 Rohwer, N., et al. Hypoxia-inducible factor 1α mediates anoikis resistance via suppression of α5 integrin. Cancer Res. 68 (2008), 10113–10120.
50. 50 Psaila, B., Lyden, D., The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 9 (2009), 285–293.
51. 51 Erler, J.T., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15 (2009), 35–44.
52. 52 Cox, T.R., et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522 (2015), 106–110.
53. 53 Oskarsson, T., et al. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14 (2014), 306–321.
54. 54 Peng, G., Liu, Y., Hypoxia-inducible factors in cancer stem cells and inflammation. Trends Pharmacol. Sci. 36 (2015), 374–383.
55. 55 Mathieu, J., et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 71 (2011), 4640–4652.
56. 56 Conley, S.J., et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 2784–2789.
57. 57 Schwab, L.P., et al. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res., 14, 2012, R6.
58. 58 Xiang, L., et al. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget 5 (2014), 12509–12527.
59. 59 Cordenonsi, M., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147 (2011), 759–772.
60. 60 Xiang, L., et al. HIF-1α and TAZ serve as reciprocal co-activators in human breast cancer cells. Oncotarget 6 (2015), 11768–11778.
61. 61 Bendinelli, P., et al. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WW domain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. Eur. J. Cancer Oxf. Engl. 1990 49 (2013), 2608–2618.
62. 62 Ma, B., et al. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Nat. Cell Biol. 17 (2015), 95–103.
63. 63 Zhang, C., et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E2047–E2056.
64. 64 Samanta, D., et al. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E5429–E5438.
65. 65 Lu, H., et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E4600–E4609.
66. 66 Zhang, H., et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E6215–E6223.
67. 67 Corzo, C.A., et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207 (2010), 2439–2453.
68. 68 Chaturvedi, P., et al. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E2120–E2129.
69. 69 Facciabene, A., et al. Tumor hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475 (2011), 226–230.
70. 70 Clambey, E.T., et al. Hypoxia-inducible factor-1α-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2784–E2793.
71. 71 Doedens, A.L., et al. Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression. Cancer Res. 70 (2010), 7465–7475.
72. 72 Hatfield, S.M., et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. J. Mol. Med. Berl. Ger. 92 (2014), 1283–1292.
73. 73 Topalian, S.L., et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
74. 74 Barsoum, I.B., et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 74 (2014), 665–674.
75. 75 Noman, M.Z., et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211 (2014), 781–790.
76. 76 Noman, M.Z., et al. Hypoxia: a key player in antitumor immune response. Am. J. Physiol. Cell Physiol. 309 (2015), C569–C579.
77. 77 Chang, C-H., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241.
78. 78 Ho, P-C., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162 (2015), 1217–1228.
79. 79 Zhang, M., et al. HIF-1α regulates the response of primary sarcomas to radiation therapy through a cell autonomous mechanism. Radiat. Res. 183 (2015), 594–609.
80. 80 Rohwer, N., Cramer, T., Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat. 14 (2011), 191–201.
81. 81 Ebos, J.M.L., Kerbel, R.S., Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8 (2011), 210–221.
82. 82 Conley, S.J., et al. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res. Treat. 150 (2015), 559–567.
83. 83 Pham, E., et al. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin. Cancer Res. 21 (2015), 808–818.
84. 84 Zhao, T., et al. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget 6 (2015), 2250–2262.
85. 85 Shen, C., Kaelin, W.G., The VHL/HIF axis in clear cell renal carcinoma. Semin. Cancer Biol. 23 (2013), 18–25.
86. 86 Keefe, S.M., et al. Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial. Ann. Oncol. 27 (2016), 1579–1585.
87. 87 Cerulean Pharma, Cerulean announces results from phase 2 clinical trial of CRLX101 and avastin combination in relapsed renal cell carcinoma. 2016.
88. 88 Zhang, H., et al. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 19579–19586.
89. 89 Chen, W., et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539 (2016), 112–117.
90. 90 Cho, H., et al. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature 539 (2016), 107–111.